Lockwood, William

Portrait photo of William Lockwood


Lockwood, William


Basic Info

Academic Rank:

Associate Professor, Pathology and Laboratory Medicine, Scientist, Integrative Oncology, British Columbia Cancer Agency


BC Cancer Agency


BC Cancer Agency

Short Bio

Born and raised in Kamloops, BC, Dr. Lockwood obtained his Ph.D. from the University of British Columbia and trained with the lung cancer research group at BC Cancer Research Centre where he worked on characterizing the genetic mechanisms underlying the development of different lung cancer subtypes. He pursued postdoctoral studies as a CIHR Jean-Francois St. Dennis Fellow in Cancer Research in the laboratory of Nobel laureate Dr. Harold Varmus, first at Memorial Sloan-Kettering Cancer Center, New York, and later at the National Human Genome Research Institute in Bethesda. There, he focused on utilizing mouse models of lung cancer to study mechanism of lung cancer initiation, progression and response to therapy and identifying novel therapeutics for lung cancer treatment. Dr. Lockwood returned to the BC Cancer Agency to begin his own research group in 2014 with a focus on understanding lung cancer biology using integrative genomics approaches and is currently a Michael Smith Foundation for Health Research Scholar and Scientist in the Integrative Oncology Department.


Academic Backgrounds

  • Post-Doctoral Fellow (Cancer Genetics), with Harold Varmus, National Human Genome Research Institute, 2010-2014
  • Post-Doctoral Fellow (Cancer Biology and Genetics), with Harold Varmus, Memorial Sloan-Kettering Cancer Center, 2009-2010
  • PhD (Pathology and Laboratory Medicine), University of British Columbia, 2009
  • BSc (Microbiology and Immunology), University of British Columbia, 2004

Awards & Recognition

Selected Publications

  • Lockwood WW†, Zejnullahu K, Bradner JE, Varmus H (2012) Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A. 109:19408-13. †Corresponding author. Highlighted in Nature Reviews Cancer (Dec. 2012) Recommended as an article of special significance by F1000.
  • Lockwood WW†, Wilson IM, Coe BP, Chari R, Pikor LA, Thu KL, Solis LM, Nunez MI, Behrens C, Yee J, English J, Murray N, Tsao MS, Minna J, Gazdar AF, Wistuba II, MacAulay CE, Lam S, Lam WL (2012) Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PLoS One. 7(5):e37775. †Corresponding author.
  • Lockwood WW*,†, Thu KL*, Lin L, Pikor LA, Chari R, Lam WL, Beer DG (2012) Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma. Clinical Cancer Research. 18:1936-46. [*co-first authorship] †Corresponding author.
  • Beverly LJ, Lockwood WW, Erdjument-Bromage H, Varmus HE (2012) Ubiquitination, localization and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1. Proc Natl Acad Sci U S A. 109:E119-26.
  • Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faça VM, Kelly-Spratt K, Wong CH, Zhang Q, Chin A, Park KS, Goodman G, Gazdar AF, Sage J, Dinulescu DM, Kucherlapati R, DePinho RA, Kemp CJ, Varmus HE, Hanash SM (2011) Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell. 20:289-99.
  • Lockwood WW†, Chari R, Coe BP, Thu KL, Garnis C, Malloff CA, Campbell J, Williams AC, Hwang D, Buys TPH, Yee J, English JC, MacAulay C, Tsao MS, Gazdar AF, Minna JD, Lam S, Lam WL (2010) Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS Medicine. 7(7):e1000315. †Corresponding author.

Current Openings & Opportunities

Current Projects In My Lab include


  • Lung Cancer
  • Cancer Biology
  • Genomics
  • Gene Discovery
  • Mouse Models
  • Targeted Therapies, Biomarkers

Lung cancer is the leading cause of cancer mortality worldwide, suffering from a late stage of disease at the time of diagnosis and a paucity of effective therapeutic strategies to treat advanced tumours. However, with our increasing understanding of lung cancer biology has come the advent of targeted therapies to combat this devastating disease. These therapies target mutated components of key cellular pathways on which tumours have become dependent on for survival, yielding drastic initial response rates without the major side effects of traditional chemotherapies. Despite these successes two major problems remain: first, the majority of lung cancer patients have tumours without mutations in targetable genes and; second, all patients eventually develop resistance to treatment with these targeted agents. In addition, since lung tumours commonly have hundreds of mutated genes, it is difficult to pinpoint those that are responsible for tumour growth and resistance to therapy, creating a clear bottleneck in the translation of laboratory findings to a clinical setting.

Dr. Lockwood’s lab utilizes an integrative strategy to address these issues. Through analysis of the genomic profiles of human lung tumours, he aims to identify novel genes and pathways that are altered during lung cancer development. Furthermore, by combining this information with the characterization of mice genetically engineered to develop lung tumours, he attempts to elucidate the key genes driving lung cancer initiation, progression and response to therapy. Lastly, by screening libraries of chemical compounds across lung cancer cells, he aims to characterize novel inhibitors of these identified genes and their corresponding pathways that show promise for use as targeted therapies. Together, this work will further our understanding of lung cancer biology and create insight toward the development of new approaches to diagnose and treat patients suffering from this disease.